BG Medicine, Inc. to Present at Lazard Capital Markets 9th Annual Healthcare
WALTHAM, Mass., Nov. 9, 2012 (GLOBE NEWSWIRE) -- BG Medicine, Inc.
(Nasdaq:BGMD), a company focused on the development and commercialization of
novel cardiovascular diagnostics, announced today that Eric Bouvier, BG
Medicine's President and CEO, will present at the Lazard Capital Markets 9^th
Annual Healthcare Conference on November 14 at 3:00 PM Eastern Time (ET) in
New York City.
To access the live and subsequently archived webcast of the presentation, go
to the "Investors" section of the Company's website at
http://investor.bg-medicine.com/events.cfm. Replays will be available on the
Company's website for 30 days after the initial presentation.
About BG Medicine, Inc.
BG Medicine, Inc. (Nasdaq:BGMD) is a life sciences company focused on the
discovery, development and commercialization of novel cardiovascular
diagnostics to address significant unmet medical needs, improve patient
outcomes and reduce healthcare costs. The Company's first commercialized
product, the BGM Galectin-3^® test for use in patients with chronic heart
failure, is available in the United States and Europe.BG Medicine is also
developing the CardioSCORE™ test, a blood test designed to aid in the
assessment of an individual's risk for near-term major cardiovascular
events.For additional information about BG Medicine, heart failure and
galectin-3 testing, please visit www.bg-medicine.com and www.galectin-3.com.
The BG Medicine Inc. logo is available at
CONTACT: Chuck Abdalian
EVP & Chief Financial Officer
BG Medicine Inc. logo
Press spacebar to pause and continue. Press esc to stop.